Pelareorep is an Oncolytics Biotech Inc program in newly diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC). Its next catalyst is a Readout in Q4 2026.
All upcoming FDA decision dates on the 2026 PDUFA calendar
Indications under review: Newly diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC); Second-line RAS-mutant, microsatellite-stable metastatic colorectal cancer; Second-line and later squamous cell anal carcinoma (SCAC). Sponsor: Oncolytics Biotech Inc (ONCY). We track 3 catalyst events for this program: 3 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.
The next tracked catalyst for Pelareorep is a Readout in Q4 2026.
No FDA decision for Pelareorep is in our archive yet.
In our records Pelareorep is under review or in development for Newly diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC); Second-line RAS-mutant, microsatellite-stable metastatic colorectal cancer.
Oncolytics Biotech Inc (ONCY).
FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.